Rovafovir etalafenamide

Rovafovir etalafenamide (development code GS-9131) is an experimental drug for the treatment of HIV-1 infection. Rovafovir etalafenamide is a nucleotide reverse transcriptase inhibitor and prodrug of GS-9148. Rovafovir etalafenamide itself has no antiviral activity, but once consumed it is metabolized through the hydrolysis of the phosphonoamidate group to generate the antiviral compound GS-9148.

The drug is being developed by Gilead Sciences.

Rovafovir etalafenamide shows antiviral activity against viruses containing major mutations associated with resistance to the nucleoside analog reverse-transcriptase inhibitors which are commonly used to treat HIV/AIDS infection.

The methods by which the drug is synthesized has been published.